Stock 002317 GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Guangdong Zhongsheng Pharmaceutical Co., Ltd.

Equities

002317

CNE100000HW4

Pharmaceuticals

End-of-day quote Shenzhen S.E.
Other stock markets
 06:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
14.9 CNY +2.19% Intraday chart for Guangdong Zhongsheng Pharmaceutical Co., Ltd. +3.98% -7.17%
Apr. 22 Guangdong Zhongsheng Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Mar. 11 Zhongsheng Pharma's Chairman to Raise Stake in Company MT

Valuation

Fiscal Period: December 2019 2020 2022 2023 2024 2025
Capitalization 1 10,203 8,853 21,822 13,607 12,632 -
Enterprise Value (EV) 1 10,203 8,853 21,822 13,607 12,632 12,632
P/E ratio 32.6 x -20.8 x 67.5 x 50.2 x 31.7 x 28.7 x
Yield - - - 1.25% - -
Capitalization / Revenue 4.03 x 4.67 x - 5.21 x 4.05 x 3.68 x
EV / Revenue 4.03 x 4.67 x - 5.21 x 4.05 x 3.68 x
EV / EBITDA 21,278,618 x -39,290,303 x - - - -
EV / FCF - - - - - -
FCF Yield - - - - - -
Price to Book 2.54 x 2.55 x - 3.15 x 2.93 x 2.65 x
Nbr of stocks (in thousands) 803,357 803,357 808,504 847,799 847,799 -
Reference price 2 12.70 11.02 26.99 16.05 14.90 14.90
Announcement Date 2/26/20 4/26/21 4/10/23 4/22/24 - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2022 2023 2024 2025
Net sales 1 2,532 1,896 - 2,611 3,120 3,432
EBITDA 479.5 -225.3 - - - -
EBIT 380.6 -324.2 - - - -
Operating Margin 15.03% -17.1% - - - -
Earnings before Tax (EBT) 378.9 -345.3 - - - -
Net income 1 317.7 -426.6 322.1 263.3 401 443
Net margin 12.55% -22.5% - 10.08% 12.85% 12.91%
EPS 2 0.3900 -0.5300 0.4000 0.3200 0.4700 0.5200
Free Cash Flow - - - - - -
FCF margin - - - - - -
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share 2 - - - 0.2000 - -
Announcement Date 2/26/20 4/26/21 4/10/23 4/22/24 - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 539.3 641.1 758 776 799
EBITDA - - - - -
EBIT - - - - -
Operating Margin - - - - -
Earnings before Tax (EBT) - - - - -
Net income - - - - -
Net margin - - - - -
EPS 2 -0.0200 0.0600 0.1400 0.0900 0.0700
Dividend per Share - - - - -
Announcement Date 4/22/24 4/22/24 - - -
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2022 2023 2024 2025
Net Debt - - - - - -
Net Cash position - - - - - -
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow - - - - - -
ROE (net income / shareholders' equity) 7.99% -11.3% - 6.58% 9.7% 9.7%
ROA (Net income/ Total Assets) 5.94% - - - 6.5% 6.5%
Assets 1 5,352 - - - 6,169 6,815
Book Value Per Share 2 4.990 4.330 - 5.100 5.090 5.620
Cash Flow per Share 2 0.3100 0.1700 - 0.2200 0.2500 0.2600
Capex - - - - - -
Capex / Sales - - - - - -
Announcement Date 2/26/20 4/26/21 4/10/23 4/22/24 - -
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
14.9
Average target price
-
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD. Stock Guangdong Zhongsheng Pharmaceutical Co., Ltd.
-7.17% 1.74B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.19% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+14.55% 231B
NOVARTIS AG Stock Novartis AG
+4.47% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.45% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 002317 Stock
  4. Financials Guangdong Zhongsheng Pharmaceutical Co., Ltd.